Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.78 |
| ▸ | CCND1 | P24385 | 4/20 | 0.78 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 1/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.48 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4869090 | 0.94 | CDK4 (0.81) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL5989829 | 0.93 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL9703488 | 0.93 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL1120445 | 0.88 | CDK4 (0.76) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL20378423 | 0.87 | HTT (0.61) | CDK4CCND1LMNAHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL6258190 | 0.86 | CDK4 (0.73) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL11366447 | 0.83 | CDK4 (1.00) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL28616424 | 0.81 | CDK4 (0.82) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL4992403 | 0.81 | CDK4 (0.78) | CDK4CCND1LMNAHTR2AHTR2C | |
| SCHEMBL21415802 | 0.81 | CDK4 (0.78) | CDK4CCND1LMNAHTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3436017-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME (US) | 2020-09-23 | — | — | EP | disclosed |
| US-10544147-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190119278-A1 | Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | MERCK SHARP & DOHME CORP. (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3436017-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | Merck Sharp & Dohme Corp. (US) | 2019-02-06 | — | — | EP | disclosed |
| US-20180200233-A1 | COMPOSITIONS FOR PREVENTING CANCERS ASSOCIATED WITH HUMAN PAPILLOMA VIRUSES | LOMA LINDA UNIVERSITY | 2018-07-19 | — | — | US | disclosed |
| US-20180200233-A1 | COMPOSITIONS FOR PREVENTING CANCERS ASSOCIATED WITH HUMAN PAPILLOMA VIRUSES | LOMA LINDA UNIVERSITY | 2018-07-19 | — | — | US | disclosed |
| WO-2017166104-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2017-10-05 | — | — | WO | disclosed |
| WO-2017172507-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2017-10-05 | — | — | WO | disclosed |
| EP-1768966-B1 | COUMPOUNDS AND METHODS FOR INHIBITING THE INTERACTION OF BCL PROTEINS WITH BINDING PARTNERS | INFINITY DISCOVERY INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7943616-B2 | Protein kinase inhibitors; astham; psoriasis; antiinflammatory agents; inflammatory bowel disorders | AVENTIS PHARMACEUTICALS INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-6706750-B1 | USEFUL IN TREATING OBESITY AND OTHER DISORDERS | VERNALIS RESEARCH LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
| EP-1377549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | Millennium Pharmaceuticals, Inc. (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-03 | — | — | US | disclosed |
| WO-2002072549-A1 | FUNCTIONALIZED HETEROCYCLES AS MODULATORS OF CHEMOKINE RECEPTOR FUNCTION AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-09-19 | — | — | WO | disclosed |
| CN-1368960-A | Indole derivatives, process for their preparation, pharmaceutical compositions containing them and their medical use | VERNALIS RES LTD (GB) | 2002-09-11 | — | — | CN | disclosed |
| EP-1202965-A1 | INDOLE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RESEARCH LIMITED (GB) | 2002-05-08 | — | — | EP | disclosed |
| WO-2001012603-A1 | INDOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR MEDICINAL APPLICATION | VERNALIS RESEARCH LIMITED (GB) | 2001-02-22 | — | — | WO | disclosed |
| US-5990094-A | SEROTONIN N-ACETYLTRANSFERASE INHIBITORS WHICH CAN SERVE AS BIOLOGICAL TOOLS THAT HELP REVEAL BIOLOGICAL FUNCTIONS FOR MELATONIN AND PINEAL SEROTONIN IN VIVO; ACETYL-COA N-ACETYL TRYPTAMINE DERIVATIVES OF GIVEN STRUCTURE | THE ROCKEFELLER UNIVERSITY (US) | 1999-11-23 | — | — | US | disclosed |
| US-5081131-A | Omega-((hetero)alkyl)benz(cd)-indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1992-01-14 | — | — | US | disclosed |
| EP-0230035-A2 | Omega-[(hetero)alkyl]benz[cd]indol-2-amines | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119278-A1 | Purine Inhibitors of Human Phosphatidylinositol 3-Kinase Delta | PIK3CD, PIK3CA, PI4KA | CDK4 565/4885CCND1 814/4885LMNA 3136/4885 |
| US-20030064991-A1 | Functionalized heterocycles as modulators of chemokine receptor function and methods of use therefor | ACKR3, CCR5, CXCR4 | CDK4 1559/4885CCND1 2593/4885LMNA 4828/4885 |
| US-10544147-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | CDK4 565/4885CCND1 814/4885LMNA 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.